A 2025 retrospective real-world study in Frontiers in Endocrinology found that after 1 year on oral semaglutide 14 mg, only around half of participants achieved clinically significant weight loss of at least 5%, which shows how real-world persistence can produce more mixed results than trial conditions
Recently, the interaction between forkhead box O4 (FOXO4) and p53 has received considerable attention as a target for senescent cells
MCBIOS 2025 Conference Leveraging AI to reconcile barriers in IO research Session Invitation
For questions that require a robust human evidence base, the individually studied substances are the cleaner reference
February 23, 2026: New Weight Loss Drug Fails to Outperform Zepbound in Clinical Trial Zepbound was not outperformed in a clinical trial of a competitors new GLP-1 weight loss drug formulation
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats